Abstract
Multiple Sclerosis is the most common non-traumatic disorder of the central nervous system and is generally regarded as an immune-mediated disorder that occurs in young adults. Since cerebrospinal fluid is in close contact with the extracellular surface of the brain, it is of great interest to examine possible biomarkers for multiple sclerosis. Proteomic studies of cerebrospinal fluid samples represent an important step towards a better understanding of the disease and may lead to the identification of clinically useful markers. Methodological advances in proteomics allowed the comparison of the protein content in different cerebrospinal fluid samples, using gel or liquid-based approaches coupled with mass spectrometry. In this paper, we discuss the advantages and limitations of the strategies employed and the potential biomarkers for multiple sclerosis identified so far using proteomics-based approaches.
Keywords: Multiple sclerosis, cerebrospinal fluid, biomarkers, proteomics, inflammatory demyelinating disease, autoimmune aetiology, heterogeneity, inflammation, neuronal lesions, magnetic resonance imaging, neurodegenerative disorders, homeostasis, mass spectrometry, gel-free techniques, proteomics-based technologies
Current Molecular Medicine
Title: Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid
Volume: 11 Issue: 4
Author(s): A. S.T. Lourenco, I. Baldeiras, M. Graos and C. B. Duarte
Affiliation:
Keywords: Multiple sclerosis, cerebrospinal fluid, biomarkers, proteomics, inflammatory demyelinating disease, autoimmune aetiology, heterogeneity, inflammation, neuronal lesions, magnetic resonance imaging, neurodegenerative disorders, homeostasis, mass spectrometry, gel-free techniques, proteomics-based technologies
Abstract: Multiple Sclerosis is the most common non-traumatic disorder of the central nervous system and is generally regarded as an immune-mediated disorder that occurs in young adults. Since cerebrospinal fluid is in close contact with the extracellular surface of the brain, it is of great interest to examine possible biomarkers for multiple sclerosis. Proteomic studies of cerebrospinal fluid samples represent an important step towards a better understanding of the disease and may lead to the identification of clinically useful markers. Methodological advances in proteomics allowed the comparison of the protein content in different cerebrospinal fluid samples, using gel or liquid-based approaches coupled with mass spectrometry. In this paper, we discuss the advantages and limitations of the strategies employed and the potential biomarkers for multiple sclerosis identified so far using proteomics-based approaches.
Export Options
About this article
Cite this article as:
S.T. Lourenco A., Baldeiras I., Graos M. and B. Duarte C., Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid, Current Molecular Medicine 2011; 11 (4) . https://dx.doi.org/10.2174/156652411795677981
DOI https://dx.doi.org/10.2174/156652411795677981 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Effects of Antioxidants in Neurodegeneration: Direct Neuroprotection against Oxidative Stress and Indirect Protection via Suppression of Gliamediated Inflammation
Current Pharmaceutical Design Novel Detection System for Plant Protein Production of Pharmaceuticals and Impact on Conformational Diseases
Protein & Peptide Letters Editorial (Thematic Issue: Microglia - A Therapeutic Target in Neurological Diseases and Disorders)
CNS & Neurological Disorders - Drug Targets Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Applications of Human Umbilical Cord Blood Cells in Central Nervous System Regeneration
Current Stem Cell Research & Therapy Enhanced Hippocampal Neurogenesis in APP/Ps1 Mouse Model of Alzheimer's Disease After Implantation of VEGF-loaded PLGA Nanospheres
Current Alzheimer Research Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Editorial [Hot topic: New Therapeutic Strategies for Treatment of Neurodegenerative Diseases (Executive Editor: Aleksey G. Kazantsev)]
Current Pharmaceutical Design Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy
Central Nervous System Agents in Medicinal Chemistry The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance
Current Alzheimer Research Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Phytochemicals Targeting Oxidative Stress, Interconnected Neuroinflammatory, and Neuroapoptotic Pathways Following Radiation
Current Neuropharmacology Healthy Gut, Healthy Brain: The Gut Microbiome in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer’s Disease
Current Medicinal Chemistry Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes
Combinatorial Chemistry & High Throughput Screening